TABLE 1.
Clinical and pathological features.
| Features | TOTAL n. (%) |
PD-L1 SP263 TPS |
PD-L1 SP263 CPS |
PD-L1 SP142 |
IHC MMRPs |
||||||
| Positive | Negative | Positive | Negative | TILs + | TILs - | NA | pMMR | lo-pa MMR | dMMR | ||
| Mean age (years) | |||||||||||
| < 60 | 27 (37.5%) |
20 (27.8%) |
7 (9.7%) |
22 (30.6%) |
5 (7%) |
19 (26.4%) |
8 (11.1%) |
/ | 19 (26.4%) |
7 (9.7%) |
1 (1.4%) |
| ≥ 60 | 45 (62.5%) |
25 (34.7%) |
20 (27.8%) |
35 (48.6%) |
10 (13.9%) |
28 (38.9%) |
7 (9.7%) |
10 (13.9%) |
40 (55.6%) |
5 (7%) |
/ |
| Anatomical location | |||||||||||
| Glans | 68 (94.4%) |
41 (56.9%) |
27 (37.5%) |
53 (73.6%) |
15 (20.8%) |
43 (59.7%) |
15 (20.8%) |
10 (13.9%) |
55 (76.4%) |
12 (16.7%) |
1 (1.4%) |
| Foreskin | 4 (5.6%) |
4 (5.6%) |
/ | 4 (5.6%) |
/ | 4 (5.6%) |
/ | / | 4 (5.6%) |
/ | / |
| T-STAGE | |||||||||||
| T1 | 24 (33.3%) |
17 (23.6%) |
7 (9.7%) |
20 (27.8%) |
4 (5.6%) |
17 (23.6%) |
5 (7%) |
2 (2.8%) |
23 (31.9%) |
1 (1.4%) |
/ |
| T2 | 25 (34.7%) |
14 (19.4%) |
11 (15.3%) |
19 (26.4%) |
6 (8.3%) |
14 (19.4%) |
7 (9.7%) |
4 (5.6%) |
17 (23.6%) |
7 (9.7%) |
1 (1.4%) |
| T3 | 17 (23.6%) |
10 (13.9%) |
7 (9.7%) |
13 (18%) |
4 (5.6%) |
12 (16.7%) |
2 (2.8%) |
3 (4.2%) |
14 (19.4%) |
3 (4.2%) |
/ |
| T4 | 5 (7%) |
3 (4.2%) |
2 (2.8%) |
4 (5.6%) |
1 (1.4%) |
4 (5.6%) |
/ | 1 (1.4%) |
4 (5.6%) |
1 (1.4%) |
/ |
| In situ | 1 (1.4%) |
1 (1.4%) |
/ | 1 (1.4%) |
/ | / | 1 (1.4%) |
/ | 1 (1.4%) |
/ | / |
| Hystological classification | |||||||||||
| USCC | 65 (90.3%) |
40 (55.6%) |
25 (34.7%) |
53 (73.6%) |
12 (16.7%) |
44 (61.1%) |
12 (16.7%) |
9 (12.5%) |
52 (72.2%) |
12 (16.7%) |
1 (1.4%) |
| Verrucous | 1 (1.4%) |
1 (1.4%) |
/ | 1 (1.4%) |
/ | 1 (1.4%) |
/ | / | 1 (1.4%) |
/ | / |
| Basaloid | 4 (5.6%) |
4 (5.6%) |
/ | 3 (4.2%) |
1 (1.4%) |
2 (2.8%) |
2 (2.8%) |
/ | 4 (5.6%) |
/ | / |
| Warty | 1 (1.4%) |
/ | 1 (1.4%) |
/ | 1 (1.4%) |
/ | / | 1 (1.4%) |
1 (1.4%) |
/ | / |
| Mixed (Warty-Basaloid) |
1 (1.4%) |
/ | 1 (1.4%) |
/ | 1 (1.4%) |
/ | 1 (1.4%) |
/ | 1 (1.4%) |
/ | / |
| Hystological grade | |||||||||||
| G1 | 18 (25%) |
9 (12.5%) |
9 (12.5%) |
14 (19.4%) |
4 (5.6%) |
10 (13.9%) |
5 (7%) |
3 (4.2%) |
14 (19.4%) |
4 (5.6%) |
/ |
| G2 | 39 (54.2%) |
26 (36.1%) |
13 (18%) |
33 (45.8%) |
6 (8.3%) |
28 (38.9%) |
6 (8.3%) |
5 (7%) |
34 (47.2%) |
4 (5.6%) |
1 (1.4%) |
| G3 | 15 (20.8%) |
10 (13.9%) |
5 (7%) |
10 (13.9%) |
5 (7%) |
9 (12.5%) |
4 (5.6%) |
2 (2.8%) |
11 (15.3%) |
4 (5.6%) |
/ |
| P16 IHC | |||||||||||
| Positive | 25 (34.7%) |
17 (23.6%) |
8 (11.1%) |
19 (26.4%) |
6 (8.3%) |
14 (19.4%) |
7 (9.7%) |
4 (5.6%) |
21 (29.2%) |
4 (5.6%) |
/ |
| Negative | 47 (65.3%) |
28 (38.9%) |
19 (26.4%) |
38 (52.8%) |
9 (12.5%) |
33 (45.8%) |
8 (11.1%) |
6 (8.3%) |
38 (52.8%) |
8 (11.1%) |
1 (1.4%) |
| HPV ISH | |||||||||||
| Positive | 13 (18%) |
7 (9.7%) |
6 (8.3%) |
8 (11.1%) |
5 (7%) |
9 (12.5%) |
1 (1.4%) |
3 (4.2%) |
10 (13.9%) |
3 (4.2%) |
/ |
| Negative | 59 (82%) |
38 (52.8%) |
21 (29.2%) |
49 (68%) |
10 (13.9%) |
38 (52.8%) |
14 (19.4%) |
7 (9.7%) |
49 (68%) |
9 (12.5%) |
1 (1.4%) |
| TOTAL | 72 (100%) | 45 (62.5%) |
27 (37.5%) |
57 (79.2%) |
15 (20.8%) |
47 (65.3%) |
15 (20.8%) |
10 (13.9%) |
59 (82%) |
12 (16.7%) |
1 (1.4%) |
TPS, tumor proportion score; CPS, combined proportion score; IHC, immunohistochemistry; MMRPs, mismatch-repair proteins; pMMRPs, proficient mismatch-repair proteins; dMMRPs, deficient mismatch-repair proteins; lo-pa MMRPs, loss/patchy mismatch-repair proteins; TILs+, tumor-infiltrating lymphocytes present; TILs-, tumor-infiltrating lymphocytes absent; NA, Not Available; USCC, usual squamous cell carcinoma.